Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Teva's new CEO shakes...

    Teva's new CEO shakes up management, to combine divisions

    Written by Ruby Khatun Khatun Published On 2017-11-30T09:15:48+05:30  |  Updated On 18 Aug 2021 2:38 PM IST

    TEL AVIV: Teva Pharmaceutical Industries Ltd's new chief executive officer ousted the company's three top division heads on Monday as he works to turn around and streamline the operations of the debt-laden drugmaker.


    CEO Kare Schultz, who joined Teva on Nov. 1, said he will combine the Israeli company's generic and specialty drugs business, as well as the research and development groups for those units.



    Shares in the world's largest generic drugmaker, which have been in a year-long freefall due to narrowing profit margins in generics and a series of pricey acquisitions, jumped as much as 6.4 percent in New York trading on Monday.

    Various media had reported last week that Teva planned to cut up to one-quarter of its 6,860-strong workforce in Israel, and a few thousand more staff in the United States.


    "Teva is taking decisive and immediate action to address external pressures and internal inefficiencies," Schultz said, adding that the company is working on a detailed restructuring plan to be unveiled in mid-December.


    Teva said Michael Hayden, the chief scientific officer, Rob Koremans, head of global specialty medicines, and Dipankar Bhattacharjee, head of the global generic medicines group, would step down at the end of the year.


    The company is saddled with nearly $35 billion in debt after its $40.5 billion acquisition of Allergan Plc's generic drug business Actavis last year. Profits from generics have slumped since that deal closed, and the CEO who engineered the purchase was forced to step down earlier this year.


    The company also appointed Michael McClellan as the permanent chief financial officer, after he held the role on an interim basis since July, and made five other executive changes at the top of the company.


    "It appears to us that the new CEO is approaching Teva with an ax in each hand, not hedge clippers or pruning shears," Wells Fargo analyst David Maris said in a research note. "We think the market will like this in the short run, but will eventually have serious questions as to whether this approach is cutting fat or muscle."


    Earlier on Monday, the Israeli Knesset's State Control Committee called an emergency meeting to discuss the reports of upcoming job cuts. Teva responded with a letter to parliament, saying it needs to take significant and comprehensive actions in order to secure its future.


    Teva, which has been selling off assets to help meet its debt payments, said in the letter it needed "deep, meaningful steps around the world," but did not give details.


    U.S.-traded shares rose 6.1 percent to $14.44 in mid-day trading and were up 3.6 percent to 5,042 Israeli shekels in Tel Aviv trading.




    (Reporting by Tova Cohen and Ari Rabinovitch; Additional reporting by Michael Erman in New York; Editing by Mark Potter and Jeffrey Benkoe)



    acquisitionsAllerganCEOcombineDipankar BhattacharjeedivisionsgenericKare SchultzmanagementMichael HaydenMichael McClellanpharma newsRob KoremansTevaTeva Pharmaceutical Industries Ltd
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok